Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools

In chronic-phase chronic myeloid leukemia (CML), tyrosine kinase inhibitors (TKIs) are the standard of care, and treatment-free remission (TFR) following the achievement of a stable deep molecular response (DMR) has become, alongside survival, a primary goal for virtually all patients. The GIMEMA CM...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2021-11, Vol.16 (6), p.823-838
Hauptverfasser:	Castagnetti, Fausto, Binotto, Gianni, Capodanno, Isabella, Billio, Atto, Calistri, Elisabetta, Cavazzini, Francesco, Crugnola, Monica, Gozzini, Antonella, Gugliotta, Gabriele, Krampera, Mauro, Lucchesi, Alessandro, Merli, Anna, Miggiano, Maria Cristina, Minotto, Claudia, Poggiaspalla, Monica, Salvucci, Marzia, Scappini, Barbara, Tiribelli, Mario, Trabacchi, Elena, Rosti, Gianantonio, Galimberti, Sara, Bonifacio, Massimiliano
Format:	Artikel
Sprache:	eng
Schlagworte:	Biomedicine Female Humans Immunology Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Medical prognosis Medicine Medicine & Public Health Oncology Prognosis Protein Kinase Inhibitors - therapeutic use Remission (Medicine) Remission Induction Therapy in Practice Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!